By Adria Calatayud

 

Physiomics PLC said Friday that it has been awarded further contracts of undisclosed value for projects with existing clients Bicycle Therapeutics PLC and Merck KGaA.

Physiomics, a U.K. oncology consultancy, said the project with U.K. biotech company Bicycle involves analysis of clinical data, while the deal with Germany's Merck is an extension to an existing project.

Both projects will be completed over the next four months, the company said.

Shares in Physiomics at 0839 GMT were up 3.7% at 7 pence.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

October 16, 2020 05:07 ET (09:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.